published meta-analysis   sensitivity analysis   studies

stem cells in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsLanzoni, 2021 0.14 [0.02; 0.96] Shi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] 0.22[0.05; 0.97]Lanzoni, 2021, Shi, 2020, Shu, 202030%165moderatenot evaluable deathsdetailed resultsLanzoni, 2021 0.11 [0.01; 0.93] Shi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] 0.20[0.04; 0.98]Lanzoni, 2021, Shi, 2020, Shu, 202030%165moderatenot evaluable deaths (time to event analysis only)detailed resultsLanzoni, 2021 0.11 [0.01; 0.93] 0.11[0.01; 0.93]Lanzoni, 202110%24NAnot evaluable clinical deteriorationdetailed resultsShu, 2020 0.27 [0.01; 5.58] 0.27[0.01; 5.58]Shu, 202010%41NAnot evaluable clinical improvementdetailed resultsShu, 2020 10.27 [1.17; 90.18] 10.27[1.17; 90.18]Shu, 202010%41NAnot evaluable clinical improvement (14-day)detailed resultsShu, 2020 10.27 [1.17; 90.18] 10.27[1.17; 90.18]Shu, 202010%41NAnot evaluable clinical improvement (28-day)detailed resultsShu, 2020 3.68 [0.18; 75.54] 3.68[0.18; 75.54]Shu, 202010%41NAnot evaluable clinical improvement (7-day)detailed resultsShu, 2020 6.72 [1.50; 30.07] 6.72[1.50; 30.07]Shu, 202010%41NAnot evaluable mechanical ventilationdetailed resultsShu, 2020 0.59 [0.02; 14.04] 0.59[0.02; 14.04]Shu, 202010%41NAnot evaluable recoverydetailed resultsLanzoni, 2021 3.46 [1.05; 11.35] 3.46[1.05; 11.35]Lanzoni, 202110%24NAnot evaluable serious adverse eventsdetailed resultsLanzoni, 2021 0.10 [0.01; 0.69] Shi, 2020 1.08 [0.04; 32.96] 0.21[0.02; 1.86]Lanzoni, 2021, Shi, 2020229%124moderatenot evaluable adverse eventsdetailed resultsLanzoni, 2021 0.18 [0.02; 1.95] Shi, 2020 0.88 [0.38; 2.03] Shu, 2020 2.48 [0.05; 132.54] 0.77[0.36; 1.68]Lanzoni, 2021, Shi, 2020, Shu, 202030%165moderatenot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-03-28 18:27 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 534 - roots T: 290